Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis (MS) status.
Epistemonikos ID: 26649f688d443137a6620b808a6274ba1b92c9ce
First added on: Mar 31, 2022